10x Genomics (TXG) Cash & Current Investments (2018 - 2026)

10x Genomics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $539.8 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 26.46% year-over-year to $539.8 million; the TTM figure through Mar 2026 stood at $539.8 million (up 26.46% YoY), while the FY2025 annual figure was $523.4 million, up 33.05% from the prior year.
• Cash & Current Investments came in at $539.8 million for Q1 2026 at 10x Genomics, up from $523.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $539.8 million in Q1 2026 to a low of $222.4 million in Q4 2022.
• A 5-year average of $394.4 million and a median of $391.4 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments sank 62.21% in 2022 and jumped 74.79% in 2023, its largest moves.
• 10x Genomics' Cash & Current Investments stood at $222.4 million in 2022, then surged by 74.79% to $388.7 million in 2023, then increased by 1.21% to $393.4 million in 2024, then jumped by 33.05% to $523.4 million in 2025, then rose by 3.14% to $539.8 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $539.8 million, $523.4 million, and $482.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison